Skip to main content
. Author manuscript; available in PMC: 2016 Nov 15.
Published in final edited form as: Cancer Res. 2015 Nov 2;75(22):4830–4838. doi: 10.1158/0008-5472.CAN-15-0709

Figure 5.

Figure 5

Amphiregulin expression is strongly suppressed following neoadjuvant letrozole treatment of human breast cancer patients. A, Amphiregulin mRNA analysis by gene expression microarray showing suppression of AREG levels following two weeks of letrozole treatment. The data represent the fold-change in AREG mRNA between the pre-treatment and 14-day biopsy specimens. B, mRNA analysis of selected ERBB family receptors and ligands in 14-day biopsy specimens, stratified by ultrasonographically-evaluated response after 90 days of neoadjuvant letrozole treatment. The between-group fold-change in expression is indicated in each case, p ≤ 0.05, **p ≤ 0.01. The following genes were also assessed and were not significantly different between the groups: AREG, BTC, HBEGF, NRG3, NRG4, EGFR, ERBB3 and ERBB4. C, Heatmap of expression of relative expression of each of the genes in Fig 5B in each of the tumors. Levels of each gene was normalized to its average level across the population.